Cancer driver genes, i.e., oncogenes and tumor suppressor genes, are involved in the acquisition of important functions in tumors, providing a selective growth advantage, allowing uncontrolled proliferation and avoiding apoptosis. It is therefore important to identify these driver genes, both for the fundamental understanding of cancer and to help finding new therapeutic targets. Although the most frequently mutated driver genes have been identified, it is believed that many more remain to be discovered, particularly for driver genes specific to some cancer types.
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In our current understanding of cancer, tumors appear when some cells acquire of mutations to identify OGs and TSGs. Also in this category, the 20/20+ method [27] 87 encodes genes with features based on their frequency and mutation types, in addition to 88 other biological information such as gene expression level in difference cancer cell 89 lines [28] or replication time. Then, 20/20+ predicts driver genes with a random forest 90 algorithm, which constitutes the first attempt to use a machine learning method in this 91 field. In [27] , the authors benchmark 8 driver gene prediction methods based on several 92 criteria including the fraction of predicted genes in CGC, the number of predicted driver 93 genes and the consistency. Three methods proved to perform similarly on all criteria, 94 and better than the five others: TUSON, MutSigCV, and 20/20+, validating the 95 relevance of combining heterogeneous information to predict cancer genes. 96 In the present paper, we propose a new method for cancer driver gene prediction 97 called Learning Oncogenes and TUmor Suppressors (LOTUS). Like 20/20+, LOTUS is 98 a machine learning-based method, meaning that it starts from a list of known driver 99 genes in order to "learn" the specificities of such genes and to identify new ones. In 100 addition, LOTUS presents two unique characteristics with respect to previous work in 101 this field. First, it combines informations from all three types of informations likely to 102 contain information to predict cancer genes (mutation frequency, functional impact, and 103 pathway-based informations). This integration of heterogeneous informations is carried 104 out in a unified mathematical and computational framework thanks to the use of kernel 105 methods [29] , and allows in principle to integrate other sources of data if available, such 106 as transcriptomic or epigenomic information. More precisely, in our implementation we 107 predict cancer driver genes based not only on gene mutations features like "Mutation 108 Frequency" and "Functional Impact" methods do, but also on known protein-protein positions of genes in a PPI network, or from both; the mathematical framework of kernel methods allows to simply combine heterogeneous data about genes (i.e., patterns 149 of somatic mutations and PPI information) in a single model. 150 Another salient feature of LOTUS is its ability to work in a pan-cancer setting, as 151 well as to predict driver genes specific to individual cancer types. In the later case, we 152 use a multitask learning strategy to jointly learn scoring functions for all cancer types 153 by sharing information about known driver genes in different cancer types. We test 154 both a default multitask learning strategy, that shares information in the same way 155 across all cancer types, and a new strategy that shares more information across similar 156 cancer types. More details about the mathematical formulation and algorithms 157 implemented in LOTUS are provided in the Material and Methods section. 158 In the following, we assess the performance of LOTUS first in the pan-cancer regime, 159 where we compare it to three state-of-the-art methods (TUSON, MutSigCV and 160 20/20+), and second in the cancer type specific regime, where we illustrate the 161 importance of the multitask learning strategies. 162 Cross-validation performance for pan-cancer driver gene 163 prediction 164 We first study the pan-cancer regime where cancer is considered as a single disease, and 165 where we search for driver genes involved in at least one type of cancer. Several 166 computational methods have been proposed to solve this problem in the past, and we 167 compare LOTUS with the three best methods in terms of performance according to a 168 recent benchmark [27] : MutSigCV [21] , which is a frequency-based method, and 169 TUSON [25] and 20/20+ [27] , which combine frequency and functional information. 170 While MutSigCV is and unsupervised method that scores candidate genes 171 independently of any training set of known drivers, TUSON and 20/20+ depend on a 172 training set, just like LOTUS. To perform a comparison as fair as possible between 173 different methods, we collect the training sets of TUSON and 20/20+, and evaluate the 174 performance of LOTUS on each of these datasets by 5-fold cross-validation (CV) as the mean number of non-driver genes that are ranked before known driver genes of the TUSON and 20/20 train sets, respectively. We note that these ranks were obtained 179 by training these two algorithms on their respective train set, and that this therefore 180 gives an advantage to TUSON and 20/20+ compared to LOTUS in the evaluation.
181
Indeed for the former two methods the training set is used both to define the score and 182 to assess the performance, while for LOTUS the CV procedure ensures that different 183 genes are used to train the model and to test its performance. However we note that the 184 20/20+ score itself is obtained by a bootstrap procedure similar to our cross-validation 185 approach [27]. This allows us to make fair comparisons between TUSON, MutSigCV 186 and LOTUS (trained on TUSON train set), on the one hand, and between 20/20+,
187
MutSigCV and LOTUS (trained on 20/20 train set), on the other hand. We further 188 note that MutSigCV also provides a ranked list of genes, but does not make the 189 difference between TSG and OG. Therefore, it is not dependent from a train set, and 190 the CE in this case is obtained by averaging the numbers of non-driver genes ranked 191 before each driver genes in the considered train set.
192
The CE for the different methods and the different training sets are presented in 193 Table 1 for OGs and in Table 2 well as the three other methods, at least on the datasets used here.
206
It is interesting to note that, for all methods, the performances obtained for OG do 207 not reach those obtained for TSG, suggesting that OG prediction is a more difficult 208 problem than TSG prediction. This reflects the fundamental difference between TSG 209 mutations and OG mutations: the first lead to loss-of-function and can pile up, while 210 the second are gain-of-function mutations and have a much more subtle nature. In 211 addition, gain-of-function can also be due to overexpression of the OG, which can arise 212 from other mechanisms than gene mutation. One way to improve the OG prediction 213 performance may be to include descriptors better suited to them, such as copy number. 214
Moreover, as mutations affecting OGs are not all likely to provide them with new 215 functionalities, many mutations on OGs present in the database and used here might 216 not bear information on OGs. Therefore, relevant information on OGs is scarce, which 217 makes OG prediction more difficult. In addition, the data themselves might also 218 contribute to difference in performance between TSG and OG prediction. For example, 219 in the case of the TUSON train set, although the TSG and OG train sets both contain 220 50 genes, the mutation matrix that we used to build the gene features contains 13, 525 221 mutations affecting TSGs and 7, 717 mutations affecting OGs. Therefore, the data are 222 richer for TSG, which might contribute to the difference in prediction performance.
223
The benefits of combining mutations and PPI informations 224 LOTUS, 20/20+, MutSigCV and TUSON differ not only by the algorithm they 225 implement, but also by the type of data they use to make predictions: in particular,
226
TUSON and 20/20+ use only mutational data while LOTUS uses PPI information in 227 addition to mutational data. To highlight the contributions of the algorithm and of the 228 PPI information to the performance of LOTUS, we ran LOTUS with 229 K genes = K mutation , or K genes = K P P I , i.e., with only mutation information, or only 230 9/35 PPI information. The results are presented in Table 3 and Table 2 ).
234
Train set \ Kernel K mutation K P P I K mutation + K P P I TUSON train set 2,333 1,565 931 20/20 train set 2,072 2,013 819 Table 3 . Consistency error of LOTUS for OG prediction in the pan-cancer setting, with different gene kernels (columns) and different gold standard sets of known OGs (rows).
Train set \ Kernel K mutation K P P I K mutation + K P P I TUSON train set 388 1,645 130 20/20 train set 901 1,858 514 Table 4 . Consistency error of LOTUS for TSG prediction in the pan-cancer setting, with different gene kernels (columns) and different gold standard sets of known TSGs (rows).
These results show that, both for OG and TSG, using both mutation and PPI 235 information dramatically improves the prediction performance over using only one type 236 of them. This underlines the fact that mutation and PPI are complementary 237 informations that are both useful for the prediction tasks. The performances obtained 238 with only PPI information are similar for OG and TSG, which seems to indicate that 239 this information contributes similarly to both prediction tasks. On the contrary, the 240 performances obtained using only mutation information are much better for TSG than 241 for OG. This is consistent with the above comment that mutation information is more 242 abundant in the database and more relevant in nature for TSG than for OG. It is also 243 consistent with the fact that using K mutation alone outperforms using K P P I alone for 244 TSGs, while the opposite is observed for OGs.
245
Performance on CGCv84 prediction in the pan-cancer regime 246 We now evaluate the generalization properties of the different methods on new unseen 247 data as external test set. This not only mitigates the potential bias in the evaluation of 248 the performance of TUSON and 20/20+ in the previous paragraph, but also allows to 249 evaluate the performance of the different methods when predicting supposedly "difficult" 250 new cancer genes, which have only been added recently in CGC. For that purpose we We observe that, again, LOTUS strongly outperforms all three other methods in this 264 setting. MutSigCV and TUSON have similar performance, and LOTUS outperforms 265 them in all settings by a 1.6-to 3-fold decrease in CE. 20/20+ has better performance 266 than MutSigCV, but has a CE 1.2 to 1.3 larger than LOTUS. We also observe that the 267 absolute performance are overall worse than in the previous cross-validation experiment, 268 which confirms the fact that genes recently added to CGC are overall harder to identify 269 than the ones known for a long time.
270

Analysis of new driver genes predicted by LOTUS 271
We now investigate the ability of LOTUS to make new driver gene predictions. For that 272 purpose we train LOTUS with the CGCv84 train set, and make predictions over the 273 complete COSMIC database (17, 948 genes). The complete results are given in 274 Supplementary Table 3 .
275
In the absence of experimental validation, we try to evaluate some of these 276 predictions based on independent sources of information. In this section, we do not consider cancer as a single disease, but as a variety of diseases 321 with different histological types and that can affect various organs. It is then important 322 to identify driver genes for each type of cancer. One way to solve this problem is to use 323 a prediction method that is trained only with driver genes known for the considered 324 cancer. Such single-task methods may however display poor performance because the 325 number of known drivers per cancer is often too small to derive a reliable model.
326
Indeed, scarce training data lead to a potential loss of statistical power as compared to 327 the problem of identification of pan-cancer driver genes were data available for all 328 cancers are used.
329
In this context, we investigate the multitask versions of LOTUS, where we predict 330 driver genes for a given cancer based on the drivers known for this cancer but also on all 331 driver genes known for other cancer types. For a given cancer type, this may improve 332 driver genes prediction by limiting the loss of statistical power compared to the 333 aforementioned single-task approach.
334
For that purpose, we derive a list of 174 cancer diseases from COSMICv84 as 335 explained in Methods. This complete list is available in Supplementary Table 1 . As 336 expected, many cancer types have only few, if any, known cancer genes ( Figure 3 ).
337
Since we want to evaluate the performance of LOTUS in a cross-validation scheme, 338
we only consider diseases with more than 4 known driver genes in order to be able to information as independent prior biological knowledge. In the single-task setting, we 386 proved that this information has significance for the prediction of cancer driver genes.
387
Because LOTUS is based on kernel methods, it is well suited to integrate other data 388 from multiple sources such as protein expression data, information from chip-seq, HiC 389 or methylation data, or new features for mutation timing as designed in [62] . Further 390 development could involve the definition of other gene kernels based on such type of 391 data, and combine them with our current gene kernel, in order to evaluate their 392 relevance in driver gene prediction. 393 We also showed how LOTUS can serve as a multitask method. It relies on a disease 394 kernel that controls how driver gene information is shared between diseases.
395
Interestingly, we showed that building a kernel based on independent biological prior 396 knowledge about disease similarity leads on average to the best prediction performance 397
with respect to single-task algorithms, and also with respect to a more generic multitask 398 learning strategy that does not incorporate knowledge about the cancer types. Again, 399 the kernel approach leaves space for integration of other types and possibly more 400 complex biological sources of information about diseases. Our multitask approach thus 401 allows to make prediction for cancer types with very few known driver genes, which 402 would be less reliable with the single-task methods. We considered here only diseases 403 with at least 4 known driver genes, in order to perform cross-validation studies, which 404 was necessary to evaluate the methods. However, it is important to note that in 405 real-case studies, at the extreme, both versions of multitask LOTUS could make driver 406 gene prediction for cancer types for which no driver gene is known.
407
Among the 174 diseases derived form the COSMIC database, we kept only 27 cancer 408 types for TSG prediction and 22 for OG prediction, for which at least four driver genes 409 were available. However, inspection of the 174 disease names indicates that there might 410 be diseases that could be grouped (for example "colorectal" and "colorectal 411 adenocarcinoma", or "skin" with "skin basal cell" or "skin squamous cell"), which 412 would have allowed to enlarge the training sets and possibly improve the predictions.
413
Future directions could be to have experts analyze and potentially modify this disease 414 list, in order to optimize the training sets, or help to derive finer disease descriptors.
415
LOTUS is a machine learning algorithm based on one-class SVM. In fact, the most 416 classical problem in machine learning is binary classification, where the task is to positives, which is expected for driver genes.
431
The one-class SVM algorithm [63] can also be used as a PU learning method, in 432 which a virtual item is chosen as the training set of negatives. We preferred this 433 approach because in preliminary studies, we found that it had slightly better 434 performances than PU learning methods and was also faster.
435
For LOTUS, as for all machine learning algorithm, the set of known driver genes is 436 critical: if this set is poorly chosen (i.e., if some genes were wrongly reported as driver 437 genes, or more likely, if the reported genes are not the best driver genes), the best 438 algorithm might not minimize the consistency error CE. To circumvent this problem, 439 we propose two new approaches for future developments: one could build a multi-step 440 algorithm that iteratively removes some genes from the positive set and labels them as 441 unknown, and add relabel as positives some of the best ranked unknown genes. We 442 believe that such an algorithm would make the set of positives converge to a more 443 relevant list. Alternatively, one could assign (finite) scores to the known driver genes 444 before performing classification and increment these scores at each step.
445
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Pan-cancer LOTUS
447
LOTUS is a new machine learning-based method to predict new cancer genes, given a 448 list of know ones. In the simplest, pan-cancer setting, we thus assume given a list of N 449 known cancer genes {g 1 , . . . , g N }, and the goal of LOTUS is to learn from them a 450 scoring function f (g), for any other gene g, that predicts how likely it is that g is also a 451 cancer gene. Since TSGs and OGs have different characteristics, we treat them 
where α 1 , . . . , α N are weights optimized during the training of OC-SVM [63], and 459 K(g, g ) is a so-called kernel function that quantifies the similarity between any two 460 genes g and g . In other words, the score of a new gene g is a weighted combination of 461 its similarities with the know cancer genes.
462
The kernel K encodes the similarity among genes. Mathematically, the only 463 constraint that K must fulfill is that it should be a symmetric positive definite 464 function [29]. This leaves a lot of freedom to create specific kernels encoding one's prior 465 knowledge about relevant information to predict cancer genes. In addition, one can 466 easily combine heterogeneous information in a single kernel by, e.g., summing together 467 two kernels based on different sources of data. In this work, we restrict ourselves to the 468 following basic kernels, and leave for future work a more exhaustive search of 469 optimization of kernels for cancer gene prediction.
470
• Mutation kernel. Given a large data set of somatic mutations in cohorts of cancer patients, we characterize each gene g by a vector Φ mutation (g) ∈ R 3 encoding 3
features. For OG prediction the three features are the number of damaging 20/35 missense mutations, the total number of missense mutations, and the entropy of the spatial distribution of the missense mutations on each gene. For TSG prediction, the features are the number of frameshift mutations, the number of LOF mutations (defined as the nonsense and frameshift mutations), and the number of splice site mutations. These features were calculated as proposed by [25] . We chose them because they were found to best discriminate OGs and TSGs by the TUSON algorithm [25] and were also all found among the most important features selected by the random forest algorithm used by the 20/20+ method [27] . Given two genes g and g represented by their 3-dimensional vectors Φ(g) and Φ(g ), we then define the mutation kernel as the inner product between these vectors:
Notice that using K mutation as a kernel in OC-SVM produces a scoring function averaging the mutation and PPI kernels: K gene (g, g ) = (K mutation (g, g ) + K P P I (g, g )) /2 .
While more complex kernel combination strategies such as multiple kernel learning 485 could be considered, we restrict ourselves to this simple kernel addition scheme to 486 illustrate the potential of our approach for heterogeneous data integration.
487
Multitask LOTUS for cancer type-specific predictions 488 The pan-cancer LOTUS approach can also be used for cancer-specific predictions, by 489 restricting the training set of known cancer genes to those cancer genes known to be 490 driver in a particular cancer type. However, for many cancer types, only few driver The extension of OC-SVM to the multitask setting is straightforwardly obtained by creating a kernel for (gene, disease) pairs of the form:
where K gene is a kernel between genes such as the one used in pan-cancer LOTUS and 502 K disease is a kernel between cancer types described below. We then simply run the 503 OC-SVM algorithm using K pair as kernel and {(g 1 , d 1 ), . . . , (g N , d N )} as training set, in 504 order to learn a cancer type-specific scoring function of the form f (g, d) that estimates 505 the probability that g is a cancer gene for cancer type d. 506 
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The choice of the disease kernel K disease influences how information is shared across 507 cancer types. One extreme situation is to take the uniform kernel K unif orm (d, d ) = 1 508 for any d, d . In that case, no distinction is made between diseases, and all known 509 cancer genes are pooled together, recovering the pan-cancer setting (with the slight 510 difference that genes may be counted several times in the training set if they appear in 511 several diseases). Another extreme situation is to take the Dirac kernel In order to leverage the benefits of multitask learning and learn disease-specific 516 models by sharing information across diseases, we consider instead the following two 517 disease kernels:
518
• First, we consider the standard multitask learning kernel:
which makes a compromise between the two extreme uniform and Dirac 519 kernels [30] . Intuitively, for a given cancer type, prediction of driver genes is made 520 by assigning twice more weight to the data available for this cancer than to the 521 data available for all other cancer types.
522
• Second, we test a more elaborate multitask version where we implement the idea that a given cancer might share various degrees of similarities with other cancers. prostate, salivary glands, skin, soft tissue, stomach, tendon, thyroid. A disease might be assigned one or several types and be associated to one or several locations. For example, neurofibroma is associated with a single localization ("nerve") and two types ("benign" and "sarcoma"), so that neurofibroma is described by a vector with three 1's and forty-seven 0's. For each disease, we construct the list of binary features by documenting every disease in the literature.
The corresponding vectors encoding the considered disease are given in Supplementary Table S2 . Finally, if Ψ(d) ∈ R 50 denotes the binary vector representation of disease d, we create the disease kernel as a simple inner product between these vectors, combined with the standard multitask kernel, i.e.: To assess the performance of a driver gene prediction method on a given gold standard of known driver genes, we score all genes in the COSMIC database and measure how well the known driver genes are ranked. For that purpose, we plot the receiver operating characteristic (ROC) curve, considering all known drivers as positive examples and all other genes in COSMIC as negative ones, and define the consistency error (CE) as
where #N is the number of negative genes, and AU C denotes the area under the ROC 550 curve. In words, CE measures the mean number of "non-driver" genes that the 551 prediction method ranks higher than known driver genes. Hence, a perfect prediction 552 method should have CE = 0, while a random predictor should have a CE near #N /2. 553
To estimate the performance of a machine learning-based prediction method that 554 estimates a scoring function from a training set of known driver genes, we use k-fold 555 cross-validation (CV) for each given gold standard set of known driver genes. In k-fold 556 CV, the gold standard set is randomly split into k subsets of roughly equal sizes. Each 557 subset is removed from the gold standard in turn, the prediction method is trained on 558 25/35 the remaining k − 1 subsets, and its CE is estimated considering the subset left apart as values {2 −5/2 , 2 −4/2 , . . . , 2 5/2 } that minimizes the mean CE over the folds.
568
Other driver prediction methods 569 We compare the performance of LOTUS to three other state-of-the-art methods: that combine frequency and functional information.
572
MutSigCV searches driver genes among significantly mutated genes which adjusts for 573 known covariates of mutation rates. The method estimates a background mutation rate 574 for each gene and patient, based on the observed silent mutations in the gene and 575 noncoding mutations in the surrounding regions. Incorporating mutational 576 heterogeneity, MutSigCV eliminates implausible driver genes that are often predicted by 577 simpler frequency-based models. For each gene, the mutational signal from the observed 578 non-silent counts are compared to the mutational background. The output of the 579 method is an ordered list of all considered genes as a function of a p-value that 580 estimates how likely this gene is to be a driver gene.
581
TUSON uses gene features that encode frequency mutations and functional impact 582 mutations. The underlying idea is that the proportion of mutation types observed in a 583 given gene can be used to predict the likelihood of this gene to be a cancer driver. After 584 having identified the most predicting parameters for OGs and TSGs based on a train 585 set (called the TUSON train set in the present paper), TUSON uses a statistical model 586 in which a p-value is derived for each gene that characterizes its potential as being an 587 26/35 OG or a TSG, then scores all genes in the COSMIC database, to obtain two ranked lists 588 of genes in increasing orders of p-values for OGs and TSGs.
589
The 20/20+ method encodes genes based on frequency and mutation types, and 590 other biological information. It uses a train set of OGs and TSGs (called the 20/20 591 train set in the present paper) to train a random forest algorithm. Then, the random 592 forest is used on the COSMIC database and the output of the method is again a list of 593 genes ranked according to their predicted score to be a driver gene [27] . We did not 594 implement this method, so we decided to evaluate its performance only on its original 595 training set: the 20/20 dataset. Moreover, we applied the same method to compute the 596 CE as for MutSigCV and TUSON, which should actually give an advantage to 20/20+, 597 since it is harder to make predictions in a cross-validation loop using a smaller set of 598 known driver genes.
599
Code and data availability 600 We implemented LOTUS and performed all experiments in R using in particular the 
